Most people diagnosed with the most common type of non-Hodgkin's lymphoma can safely skip radiation treatment after a clear PET scan, according to new clinical trial results released today at the 61st American Society of ...
Dec 8, 2019
0
7
A new, experimental immunotherapy can put patients with B-cell non-Hodgkin lymphoma (NHL) that is resistant to or has come back after multiple other therapies, including CAR T therapy, into remission. A global, multi-center ...
Dec 7, 2019
0
4
A collaboration between the Griffith Institute for Drug Discovery (GRIDD) and multiple clinical research institutes has led to an exciting discovery in cancer research.
Nov 20, 2019
0
25
Pemphigus, an autoimmune disease mediated by B cells and which causes painful blisters and sores on the skin and mucous membranes, is a rare chronic autoimmune condition that can be fatal if not treated. Treatment for pemphigus, ...
Nov 12, 2019
0
1
A new cancer clinical trial has opened at the M Health Fairview University of Minnesota Medical Center that leverages the groundbreaking research on stem cells and natural killer (NK) cells done at the Masonic Cancer Center ...
Oct 21, 2019
0
4
The field of immunotherapy has revolutionized the way people with incurable cancers are treated, saving the lives of many people whose disease would have otherwise been seen as a death sentence. Despite its success in treating ...
Oct 16, 2019
0
4
The first CAR T cell therapy targeting the B cell-activating factor receptor on cancerous cells eradicated CD19-targeted therapy-resistant human leukemia and lymphoma cells in animal models, according to City of Hope research ...
Sep 25, 2019
0
163
(HealthDay)—Overall survival among older adults with diffuse large B-cell lymphoma (DLBCL) has improved over time, but five-year survival is less than 40 percent, according to a study published online June 12 in Leukemia ...
Jul 1, 2019
0
0
Henry Ford Cancer Institute has treated its first patient with CAR T-cell therapy, an approach that uses engineered cells from a patient's immune system to destroy cancer. The altered cells remain active for years after the ...
Jun 18, 2019
0
3
Miguel Gallardo, researcher and coordinator of the H12O-CNIO Haematological Malignancies Clinical Research Unit headed by Joaquín Martínez at the Spanish National Cancer Research Centre (CNIO), has participated in a study ...
May 27, 2019
0
2
